AsiaNet-Pakistan Premier Editorial Content and Press Release Distribution Service
Karachi, Sanofi-Aventis Pakistan Limited, a leading pharmaceutical company, held a virtual meeting of its Board of Directors on August 25, 2023, where key recommendations and financial results for the half year ended June 30, 2023, were discussed and finalized.
In light of the discussions held during the electronic meeting, the Board of Directors recommended the following proposals:
1. Cash Dividend: Nil
2. Bonus Shares: Nil
3. Right Shares: Nil
4. Any Other Entitlement or Corporate Action: Nil
5. Any Other Price-Sensitive Information: Nil
These recommendations are in line with the company’s strategic vision and prevailing market conditions.
In addition to these recommendations, the company also released its financial results for the half year and quarter ended June 30, 2023. The financial performance, as summarized in Annexure-A, reflects key metrics related to net sales, gross profit, distribution costs, administrative expenses, and more.
The half-year financial summary outlines the following key data (all figures in Rupees ‘000):
Net Sales: 10,047,849
Gross Profit: 2,546,347
Operating (Loss) / Profit: (170,311)
(Loss) / Earnings Per Share (Basic and Diluted): (54.16)
The detailed financial report provides insights into the company’s operational performance, with comparisons to the same period in the previous year, June 30, 2022.
Sanofi-Aventis Pakistan Limited remains committed to maintaining transparency and timely communication with its stakeholders. The company’s adherence to corporate governance practices, strategic decisions, and financial reporting reflects its dedication to investor confidence and regulatory compliance.
The post Sanofi-Aventis Pakistan Limited Announces Board Recommendations and Releases Financial Results for Half Year Ended June 30, 2023 appeared first on Pakistan Company News.